TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30282826
Drug: Aldesleukin (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldesleukin (recombinant human IL-2) at a dose of 0.26 × 106 IU/m2 every 3 days
Study: 30283914
Drug: Daily meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily meals preparation and service
Study: 30284154
Drug: Everolimus (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (orally administered)
Study: 30285518
Drug: Telisotuzumab vedotin
Normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telisotuzumab vedotin (Teliso-V) 2.4 to 3.0 mg/kg
Study: 30285741
Drug: Rectal pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal pressure measurement
Study: 30285990
Drug: Unfiltered nanofat
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfiltered nanofat injections
Study: 30286724
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen (FOLFOX: 5FU, leucovorin plus oxaliplatin)
Study: 30286821
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor antagonist (MRA) therapy
Study: 30287268
Drug: Recruitment via
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment via national registers, treatment centers, and social media
Study: 30287613
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) of second-line antituberculosis drugs
Study: 30287613
Drug: Drug concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug concentrations of pyrazinamide, ethambutol, levofloxacin, moxifloxacin, cycloserine, prothionamide, para-aminosalicylate, and amikacin
Study: 30287613
Drug: MIC determination
Normalized name: MIC
DrugBank: Methyl isocyanate (DB12765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIC determination of pyrazinamide and other drugs
Study: 30287673
Drug: Core treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core treatment for osteoarthritis in primary healthcare
Study: 30288127
Drug: Video-call smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-call smoking cessation intervention (8 sessions of 30 minutes each, with active nicotine patches for 8 weeks)
Study: 30288127
Drug: Voice-call smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice-call smoking cessation intervention (8 sessions of 30 minutes each, with active nicotine patches for 8 weeks)
Study: 30288327
Drug: Rifaximin-α 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin-α 550 mg
Study: 30288700
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (0.5 mg) injections
Study: 30289425
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (WP) supplementation (30 g, 2 times/d)
Study: 30289425
Drug: Collagen peptides
Normalized name: CASTOR OIL 100 g in 100 mL TOPICAL OIL [Anyi Beauty Biotin With Collagen Peptides Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen peptides (CP) supplementation (30 g, 2 times/d)
Study: 30289805
Drug: TriMix-100 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: TriMix-100 g
Study: 30289805
Drug: TriMix-300 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: TriMix-300 g
Study: 30289805
Drug: TriMix-300 g with
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TriMix-300 g with HTI-300 g
Study: 30289805
Drug: TriMix-300 g with
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TriMix-300 g with HTI-600 g
Study: 30289805
Drug: TriMix-300 g with
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TriMix-300 g with HTI-900 g
Study: 30291112
Drug: Eculizumab 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab 600 mg weekly for 4 weeks, then 900 mg every other week through week 26
Study: 30291834
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine toothbrushing three times daily for 5 days before and after surgery
Study: 30292651
Drug: MR haplotype
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR haplotype 1 (G-A haplotype)
Study: 30294708
Drug: 4.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 g/day multimatrix mesalamine tablets once daily for eight weeks (acute phase)
Study: 30294708
Drug: 2.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/day multimatrix mesalamine for 12 months (maintenance phase)
Study: 30295389
Drug: Episodic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic treatment (n=75)
Study: 30295389
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment (n=28)
Study: 30295816
Drug: Oral clomiphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clomiphene citrate (50 mg) once daily for 30 days
Study: 30296681
Drug: pNGVL4a-Sig/E7(detox)/HSP70 DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine followed by TA-HPV boost through skin scarification
Study: 30297124
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (qHPV) administered at 0, 2, and 6 months
Study: 30297385
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg orally every day plus bortezomib 1.3 mg/m² IV on days 1, 4, 8, and 11 of a 28-day cycle
Study: 30297879
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rhEPO) treatment
Study: 30298037
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for Insomnia Severity, details not available
Study: 30298070
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of 20-30% iron-saturated bovine lactoferrin (bLf) twice a day
Study: 30298070
Drug: 329.7 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 329.7 mg of ferrous sulfate once a day (control)
Study: 30298340
Drug: Immunosignature analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosignature analysis using a 256-peptide signature derived from serum antibodies.
Study: 30298340
Drug: Immunosignature analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosignature analysis using a 654-peptide signature derived from serum antibodies.
Study: 30298381
Drug: Palliative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative radiotherapy (RT) at a total dose of 20 Gy delivered BID in two consecutive days.
Study: 30298444
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (1.5 pmol/kg/min dissolved in 500 ml of 0.9% saline)
Study: 30298444
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 ml of 0.9% saline)
Study: 30298593
Drug: Second-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation drug-eluting stents (DES-II)
Study: 30299230
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous (iv) alteplase (0.6 mg/kg body weight)
Study: 30302599
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily with mFOLFOX-6 + bevacizumab
Study: 30302599
Drug: Everolimus 7.5
Normalized name: everolimus 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 7.5 mg daily with mFOLFOX-6 + bevacizumab (recommended phase II dose)
Study: 30305055
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of obatoclax and TRAIL
Study: 30305103
Drug: Online Emotion
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online Emotion Regulation Individual Therapy for Adolescents (ERITA)
Study: 30305449
Drug: Intrathecal rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intrathecal rituximab (25 mg with a 1-week interval)
Study: 30305961
Drug: Nitrate-rich fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich fruit and vegetable liquid supplement (FVS, AMPED NOx, Isagenix International LLC)
Study: 30307350
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of 20% intravenous lipid emulsion
Study: 30309472
Drug: Home fetal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home fetal heart rate monitoring (FHRM) twice daily with a Doppler monitor and weekly or biweekly fetal echocardiograms.
Study: 30309758
Drug: Obinutuzumab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles)
Study: 30309993
Drug: Flavoured cigar
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flavoured cigar (apple, cream, original, wine)
Study: 30310267
Drug: Ranibizumab with
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab with photodynamic therapy (PDT group)
Study: 30311073
Drug: HUMAN (manually-adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HUMAN (manually-adapted target controlled infusion protocol)
Study: 30312717
Drug: Salvage low-dose-rate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage low-dose-rate (LDR) brachytherapy
Study: 30314417
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral treatment with additional one-on-one self-efficacy enhancement sessions
Study: 30317671
Drug: ixekizumab 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: ixekizumab 160 mg at Week 0, 80 mg every 2 weeks through Week 12, and 80 mg every 4 weeks thereafter up to Week 244
Study: 30318513
Drug: ARQ 761
Normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ 761 (β-lapachone analogue) at a maximum tolerated dose of 390 mg/m, administered on three schedules (weekly, every other week, 2/3 weeks)
Study: 30318646
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) dose
Study: 30319400
Drug: Metronomic four-drug
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic four-drug regimen
Study: 30319729
Drug: Nonthermal Pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonthermal Pulsed Ultrasound Treatment
Study: 30320410
Drug: Factors influencing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors influencing implant decision
Study: 30321257
Drug: Cox proportional
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cox proportional hazards models adjusted for various factors including age, sex, diabetes mellitus, cardiovascular disease, estimated glomerular filtration rate, urine protein:creatinine ratio, high-sensitivity C-reactive protein, and use of renin-angiotensin-aldosterone system inhibitors or statins.
Study: 30321314
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of both NNRTI/nucleoside reverse transcriptase inhibitor PDR
Study: 30323658
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard fractionated radiotherapy): 50.4 Gy in 28 fractions plus a sequential electron boost of 10 Gy in 4 fractions.
Study: 30323863
Drug: Sublingual allergen
Normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual allergen immunotherapy (SLIT) with house dust mite (HDM) extract
Study: 30323946
Drug: Daily activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activity feedback via smartwatch over a 9-hour period
Study: 31726452
Drug: BoNT-A injection
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT-A injection
Study: 30324586
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg bid) with Tamoxifen (60 mg loading dose qd days 10-13, 20 mg qd days 14-26)
Study: 30324586
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg bid) with Anastrozole (1 mg qd days 10-19)
Study: 30324586
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg bid) with Letrozole (2.5 mg qd days 10-38)
Study: 30324586
Drug: Olaparib monotherapy
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib monotherapy (300 mg bid continuously)
Study: 30325534
Drug: Ixekizumab (160-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (160-mg loading dose, 80 mg every 2 weeks for the first 12 weeks, then 80 mg every 4 weeks until Week 52)
Study: 30325534
Drug: Treatment Withdrawal
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Withdrawal Period (Weeks 52 to 100)
Study: 30325534
Drug: Treatment Withdrawal
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Withdrawal Period
Study: 30325779
Drug: HIV-infected individuals
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-infected individuals with reduced subcutaneous adipose tissue (SAT)
Study: 30326301
Drug: Pan-enteric capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pan-enteric capsule endoscopy (PCE)
Study: 30326968
Drug: Centralized clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centralized clinical data and biological samples collection
Study: 30326968
Drug: Biological samples
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biological samples (blood, saliva, endoscopic ultrasound-guided fine needle aspiration materials, fine needle biopsy of metastases, and surgically resected tissue)
Study: 30327612
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of energy
Study: 30327731
Drug: Subacromial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial injection with 40 mg of Methylprednisolone Acetate and 2 ml of Lidocaine
Study: 30328062
Drug: Manual preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual preparation of fecal microbiota
Study: 30328062
Drug: Automatic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic preparation of fecal microbiota
Study: 30328739
Drug: Potential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential treatment for UI
Study: 30333050
Drug: Oral debriefing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral debriefing
Study: 30333050
Drug: Oral debriefing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral debriefing assisted by video
Study: 30333052
Drug: Mindfulness and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness and PAP (Physical Activity on Prescription)
Study: 30333224
Drug: Cerdulatinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerdulatinib (oral administration, dose-escalation, once-daily or twice-daily schedules)
Study: 30333224
Drug: Cerdulatinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerdulatinib (oral administration)
Study: 30334521
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tests (TST and IGRAs)
Study: 30334527
Drug: Contrast volume
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast volume quartile Q1 (≤100 ml)
Study: 30334527
Drug: Contrast volume
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast volume quartile Q2 (101-140 ml)
Study: 30334527
Drug: Contrast volume
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast volume quartile Q3 (141-200 ml)
Study: 30334527
Drug: Contrast volume
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast volume quartile Q4 (>200 ml)
Study: 30334909
Drug: docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 100 mg/m² (n=84)
Study: 30334909
Drug: doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin 75 mg/m² (n=97)
Study: 30335559
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI (glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler)
Study: 31863283
Drug: Sequential afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sequential afatinib and osimertinib
Study: 30336828
Drug: Therapy initiation
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy initiation
Study: 30337358
Drug: Sotatercept (≥0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept (≥0.1 mg/kg) in non-transfusion-dependent β-thalassemia
Study: 30337358
Drug: Sotatercept (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept (1.0 mg/kg) in transfusion-dependent β-thalassemia
Study: 30338261
Drug: IV Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Ibuprofen
Study: 30339892
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tramadol and paracetamol
Study: 30339892
Drug: Standardised take-home
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standardised take-home analgesic and PONV strategies
Study: 30340199
Drug: Ruxolitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (5 mg, 10 mg, and 15 mg twice daily)
Study: 30340532
Drug: Intracoronary morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary morphine (1 mg)
Study: 30341043
Drug: Weekly motivational
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly motivational emails during the treatment phase
Study: 30341051
Drug: Personal coaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal coaching intervention (monthly calls with limited app components)
Study: 30341664
Drug: Patient insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient insulin injection technique (IT)
Study: 30341664
Drug: Nurse insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse insulin injection technique (IT)
Study: 30341664
Drug: Patient insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient insulin injection technique (IT) score
Study: 30341681
Drug: Salt excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt excretion measurement
Study: 30342919
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of D7-cholesterol
Study: 30343026
Drug: Daily co-formulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily co-formulated tenofovir disoproxil fumarate and emtricitabine as HIV PrEP
Study: 30343254
Drug: FOLFIRINOX induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX induction therapy
Study: 30343526
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (defined as serum 25(OH)D < 10 ng/mL) in ENKTL patients
Study: 30343614
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for three cycles before radical cystectomy (RC)
Study: 30343896
Drug: PLB-1001 (MET
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLB-1001 (MET kinase inhibitor)
Study: 30344036
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use disorder diagnosis
Study: 30344063
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Statins (both drugs)
Study: 30344179
Drug: Geriatric co-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatric co-management with proactive consultation for low-risk patients, co-management by geriatric nurse for high-risk patients, and additional medication review for patients with acute geriatric problems.
Study: 30345376
Drug: Concurrent systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent systemic disease
Study: 30346260
Drug: Endovascular stroke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular stroke treatment
Study: 30348127
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (docetaxel and cyclophosphamide, TC)
Study: 30348216
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus Sunitinib (50 mg/day, 4 weeks on/2 weeks off)
Study: 30348216
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus Pazopanib (800 mg/day)